Small molecule inhibitors of anthrax lethal factor toxin
摘要:
This manuscript describes the preparation of new small molecule inhibitors of Bacillus anthracis lethal factor. Our starting point was the symmetrical, bis-quinolinyl compound 1 (NSC 12155). Optimization of one half of this molecule led to new LF inhibitors that were desymmetrized to afford more drug-like compounds. (C) 2013 Elsevier Ltd. All rights reserved.
HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES
申请人:SYNTEX PHARMACEUTICALS LTD.
公开号:EP0693062A1
公开(公告)日:1996-01-24
US5428037A
申请人:——
公开号:US5428037A
公开(公告)日:1995-06-27
US5545645A
申请人:——
公开号:US5545645A
公开(公告)日:1996-08-13
[EN] HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES<br/>[FR] DERIVES HETEROCYCLIQUES UTILISES DANS LE TRAITEMENT DE L'ISCHEMIE ET D'AUTRES PATHOLOGIES ASSOCIEES
申请人:SYNTEX PHARMACEUTICALS LIMITED
公开号:WO1994024116A1
公开(公告)日:1994-10-27
(EN) Novel substituted piperidines and piperazines or the pharmaceutically acceptable acid addition salts thereof, are calcium and/or sodium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, and also for treatment of spinal injuries.(FR) L'invention concerne de nouvelles pipéridines et pipérazines substituées ou des sels d'addition d'acide pharmaceutiquement acceptables de ces derniers qui constituent des antagonistes des canaux à calcium et/ou à sodium, et sont utiles pour le traitement de mammifères présentant diverses pathologies telles que l'attaque, l'épilepsie, l'hypertension, l'angine, la migraine, l'arythmie, la thrombose, l'embolie et également pour le traitement de lésions spinales.
Small molecule inhibitors of anthrax lethal factor toxin
作者:John D. Williams、Atiyya R. Khan、Steven C. Cardinale、Michelle M. Butler、Terry L. Bowlin、Norton P. Peet
DOI:10.1016/j.bmc.2013.11.009
日期:2014.1
This manuscript describes the preparation of new small molecule inhibitors of Bacillus anthracis lethal factor. Our starting point was the symmetrical, bis-quinolinyl compound 1 (NSC 12155). Optimization of one half of this molecule led to new LF inhibitors that were desymmetrized to afford more drug-like compounds. (C) 2013 Elsevier Ltd. All rights reserved.